Literature DB >> 29360580

Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer.

Tamara Knific1, Katja Vouk1, Špela Smrkolj2, Cornelia Prehn3, Jerzy Adamski4, Tea Lanišnik Rižner5.   

Abstract

In endometrial cancer, biomarkers for preoperative identification of patients with low risk for disease progression would enable stratification according to the extent of surgery needed, and would avoid the complications that can be associated with radical surgery. A panel of proteins, amino acids, enzymes, and miRNA has been investigated as potential biomarkers for endometrial cancer. At the time of the manuscript submission targeted metabolomics/lipidomics approaches have not been applied to biomarker research in endometrial cancer. Using electrospray ionization-tandem mass spectrometry we quantified 163 metabolites in 126 plasma samples (61 patients with endometrial cancer, 65 control patients). Three single phosphatidylcholines were identified with significantly decreased levels in patients with endometrial cancer. A diagnostic model was defined as the ratio between acylcarnitine C16 and phosphatidylcholine PCae C40:1, the ratio between proline and tyrosine, and the ratio between the two phosphatidylcholines PCaa C42:0 and PCae C44:5; which provided sensitivity of 85.25%, specificity of 69.23%, and AUC of 0.837. Addition of smoking status further improved the constructed diagnostic model (AUC = 0.855). The presence of the major prognostic factors of deep myometrial invasion and lymphovascular invasion were also associated with altered metabolite concentrations. A prognostic model for deep myometrial invasion included the ratio between two hydroxysphingomyelins SMOH C14:1 and SMOH C24:1, and the ratio between two phosphatidylcholines PCaa C40:2 and PCaa C42:6, which provided sensitivity of 81.25%, specificity of 86.36%, and AUC of 0.857. The model for lymphovascular invasion included the ratio between two phosphatidylcholines PCaa C34:4 and PCae C38:3, and the ratio between acylcarnitine C16:2 and phosphatidylcholine PCaa C38:1, which provided sensitivity of 88.89%, specificity of 84.31%, and AUC of 0.935.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Chromatography; Diagnosis; Endometrial cancer; Metabolomics; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 29360580     DOI: 10.1016/j.jsbmb.2018.01.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  13 in total

1.  Applications of Lipidomics in Tumor Diagnosis and Therapy.

Authors:  Yuping Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Metabolomic analysis of endometrial cancer by high-resolution magic angle spinning NMR spectroscopy.

Authors:  Senem Arda Düz; Akın Mumcu; Berat Doğan; Ercan Yılmaz; Ebru İnci Çoşkun; Erdinç Sarıdogan; Görkem Tuncay; Abdullah Karaer
Journal:  Arch Gynecol Obstet       Date:  2022-05-14       Impact factor: 2.344

3.  Multi-Omic Profiling of Multi-Biosamples Reveals the Role of Amino Acid and Nucleotide Metabolism in Endometrial Cancer.

Authors:  Runqiu Yi; Liying Xie; Xiaoqing Wang; Chengpin Shen; Xiaojun Chen; Liang Qiao
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

4.  Blood Metabolites Associate with Prognosis in Endometrial Cancer.

Authors:  Elin Strand; Ingvild L Tangen; Kristine E Fasmer; Havjin Jacob; Mari K Halle; Erling A Hoivik; Bert Delvoux; Jone Trovik; Ingfrid S Haldorsen; Andrea Romano; Camilla Krakstad
Journal:  Metabolites       Date:  2019-12-14

5.  Lipidomics of the chicken egg yolk: high-resolution mass spectrometric characterization of nutritional lipid families.

Authors:  Paul L Wood; William Muir; Undine Christmann; Philippa Gibbons; Courtney L Hancock; Cathleen M Poole; Audrey L Emery; Jesse R Poovey; Casey Hagg; Jon H Scarborough; Jordon S Christopher; Alexander T Dixon; Dustin J Craney
Journal:  Poult Sci       Date:  2020-11-17       Impact factor: 3.352

Review 6.  Metabolomics for Diagnosis and Prognosis of Uterine Diseases? A Systematic Review.

Authors:  Janina Tokarz; Jerzy Adamski; Tea Lanišnik Rižner
Journal:  J Pers Med       Date:  2020-12-21

7.  Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer.

Authors:  Kelechi Njoku; Amy E Campbell; Bethany Geary; Michelle L MacKintosh; Abigail E Derbyshire; Sarah J Kitson; Vanitha N Sivalingam; Andrew Pierce; Anthony D Whetton; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.575

8.  Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.

Authors:  Hilde Engerud; Kirsten Hope; Hege Fredriksen Berg; Kristine Eldevik Fasmer; Ingvild Løberg Tangen; Ingfrid Salvesen Haldorsen; Jone Trovik; Camilla Krakstad
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

Review 9.  Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.

Authors:  Kelechi Njoku; Caroline J Sutton; Anthony D Whetton; Emma J Crosbie
Journal:  Metabolites       Date:  2020-07-31

10.  Prospective analysis of circulating metabolites and endometrial cancer risk.

Authors:  Laure Dossus; Eirini Kouloura; Carine Biessy; Vivian Viallon; Alexandros P Siskos; Niki Dimou; Sabina Rinaldi; Melissa A Merritt; Naomi Allen; Renee Fortner; Rudolf Kaaks; Elisabete Weiderpass; Inger T Gram; Joseph A Rothwell; Lucie Lécuyer; Gianluca Severi; Matthias B Schulze; Therese Haugdahl Nøst; Marta Crous-Bou; Maria-Jose Sánchez; Pilar Amiano; Sandra M Colorado-Yohar; Aurelio Barricarte Gurrea; Julie A Schmidt; Domenico Palli; Claudia Agnoli; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; Roel Vermeulen; Alicia K Heath; Sofia Christakoudi; Konstantinos K Tsilidis; Ruth C Travis; Marc J Gunter; Hector C Keun
Journal:  Gynecol Oncol       Date:  2021-06-05       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.